|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
The Benefit to Radium-223 Added to Cabozantinib for Patients With Renal Cell Carcinoma With Bone Metastasis, RadiCaL
|
Rana McKay, MD, and Alicia Morgans, MD, MPH
Rana McKay joins Alicia Morgans to discuss the RadiCaL trial, a study looking at metastatic kidney cancer and the use of radium in that population. The trial is a phase II trial, taking patients with RCC with bone metastases and randomizing them 1:1 to receive radium with cabozantinib versus cabozantinib alone. The primary endpoint of RadiCaL is a reduction in symptomatic skeletal event-free survival.
|
|
|
|
|
|
|
|
|
|
|
|
KEYNOTE-564 Shows Overall Survival Benefit in Kidney Cancer with Pembrolizumab
|
Toni Choueiri, MD
Alicia Morgans interviews Toni Choueiri about the results of the KEYNOTE-564 trial, marking a significant milestone in kidney cancer treatment with pembrolizumab showing an overall survival benefit as an adjuvant therapy.
|
|
|
|
|
|
|
|
|
|
|
| Cabozantinib and Nivolumab Combination Therapy Shows Durable Efficacy in Advanced Kidney Cancer |
María T. Bourlon, MD, MSc
Pedro Barata and María Bourlon discuss the CheckMate 9ER trial's 55-month follow-up, revealing the enduring benefits of cabozantinib plus nivolumab over sunitinib in untreated advanced renal cell carcinoma. The trial highlights significant advancements in overall survival, progression-free survival, and response rates, alongside improved quality of life for patients. |
|
|
|
|
|
|
|
|
|
|
| Key Updates in Kidney Cancer |
| Rana R. McKay, MD |
| Rana McKay discussed key updates in kidney cancer research at the 2024 Southern California Genitourinary Cancer Research Forum, highlighting trends in renal cell carcinoma incidence, the significance of variant histologies, and advancements in treatment modalities such as combination therapies. Her presentation emphasized the importance of ongoing research efforts to refine treatment strategies and improve outcomes for individuals with kidney cancer. |
|
|
|
|
|
| RCC Case-Based Trial Discussions: Localized RCC, Front-Line RCC, Salvage RCC, Non-Clear Cell RCC |
| Rana R. McKay, MD, Nataliya Mar, MD, Brian Shuch, MD, Wesley Yip, MD, and Jun Gong, MD |
| The 2024 Southern California Genitourinary Cancer Research Forum featured discussions on kidney cancer trials, covering localized RCC, front-line RCC, salvage RCC, and non-clear cell RCC. Moderator Dr. Monty Pal highlighted trials like PROBE and SAMURAI for localized RCC, while Dr. Rana McKay discussed trials like the OPTIC RCC Study for front-line metastatic RCC. Post first-line RCC trials and non-clear cell kidney cancer trials were also explored, providing insights into ongoing research efforts in Southern California. |
|
|
|
|
|
|
|
|
|
|
| Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy |
| Andrew Hahn, MD |
| Andrew Hahn presents on the role of cytoreductive nephrectomy for patients with metastatic sarcomatoid and/or rhabdoid renal cell carcinoma treated with immune checkpoint therapy. His study, involving 157 patients across two tertiary cancer centers, found that cytoreductive nephrectomy was not associated with improved treatment duration or overall survival from immune checkpoint therapy initiation. |
|
|
|
|
|
| Nivolumab plus Ipilimumab vs Sunitinib for First-Line Treatment of Advanced RCC: Long-Term Follow-Up Data from the Phase 3 CheckMate 214 Trial
|
| Nizar M. Tannir, MD, FACP
|
| Nizar Tannir presented long-term follow-up data from the phase 3 CheckMate 214 trial, comparing first-line treatment options for advanced renal cell carcinoma (RCC). The study revealed that nivolumab plus ipilimumab provided substantial long-term survival benefits over sunitinib, with superior overall survival and progression-free survival in intermediate/poor-risk patients.
|
|
|
|
|
|
| Subgroup Analyses of Efficacy Outcomes by Baseline Tumor Size in the Phase 3, Open-label CLEAR Trial |
| Viktor Grünwald, MD |
| Viktor Grünwald presents subgroup analyses of efficacy outcomes by baseline tumor size in the phase 3 CLEAR trial. The study included treatment-naïve patients with advanced RCC randomized to receive lenvatinib plus pembrolizumab, showing benefits in progression-free survival, overall survival, and objective response rate across all tumor size categories. These findings support the use of lenvatinib plus pembrolizumab as a first-line treatment for advanced RCC regardless of baseline tumor size. |
|
|
|
|
|
| Pembrolizumab + Axitinib Versus Sunitinib as First-Line Therapy for Advanced Clear Cell RCC: 5-Year Analysis of KEYNOTE-426
|
| Brian I. Rini, MD, FASCO
|
| Brian Rini presents the 5-year analysis of the KEYNOTE-426 trial at the 2023 ASCO Annual Meeting, evaluating pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell RCC. The study demonstrated continued benefits in overall survival, PFS, and objective response rate with pembrolizumab plus axitinib compared to sunitinib, supporting its use as a standard of care for previously untreated advanced clear cell RCC.
|
|
|
|
|
|
|
|
|
|
|
|
